Charles Rixey

Charles Rixey is a former marine who joined DRASTIC in researching the origins of SARS-CoV-2, and pointing out false data and other problems in the zoonosis origins story.

Leadership During the COVID-19 Pandemic

Resources

Interviews

  • July 4, 2022 JJ Couey Gigaohm Biological 4th of July with Charles Rixey: Gigaohm Biological High Resistance Low Noise Information Brief 2)

Detailed discussion of significance forFrancis Collins Blog & Jesse Bloom research @ 20min ~

NIH Directors Blog

Mapping Which Coronavirus Variants Will Resist Antibody Treatments

Posted on February 9th, 2021 by Dr. Francis Collins You may have heard about the new variants of SARS-CoV-2—the coronavirus that causes COVID-19—that have appeared in other parts of the world and have now been detected in the United States. These variants, particularly one called B.1.351 that was first identified in South Africa, have raised growing concerns about the extent to which their mutations might help them evade current antibody treatments and highly effective vaccines.

While researchers take a closer look, it’s already possible in the laboratory to predict which mutations will help SARS-CoV-2 evade our therapies and vaccines, and even to prepare for the emergence of new mutations before they occur. In fact, an NIH-funded study, which originally appeared as a bioRxiv pre-print in November and was recently peer-reviewed and published in Science, has done exactly that. In the study, researchers mapped all possible mutations that would allow SARS-CoV-2 to resist treatment with three different monoclonal antibodies developed for treatment of COVID-19 [1].

The work, led by Jesse Bloom, Allison Greaney, and Tyler Starr, Fred Hutchinson Cancer Center, Seattle, focused on the receptor binding domain (RBD), a key region of the spike protein that studs SARS-CoV-2’s outer surface. The virus uses RBD to anchor itself to the ACE2 receptor of human cells before infecting them. That makes the RBD a prime target for the antibodies that our bodies generate to defend against the virus.(https://web.archive.org/web/20210216103922/https://directorsblog.nih.gov/2021/02/09/mapping-which-coronavirus-variants-will-resist-antibody-treatments/)

Print/export